NCT02819999 - A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Rovalpituzumab Tesirine

Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).

DRUG

Cisplatin

DRUG

Etoposide

Trial Locations (11)

University of Pittsburgh, Pittsburgh

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Cancer Institute of Florida, Orlando

University Hospital of Cleveland, Cleveland

Cleveland Clinic, Cleveland

Oncology Hematology Care, Cincinnati

Washington University, St Louis

Texas Oncology, Fort Worth

Texas Oncology, San Antonio

University of Colorado, Aurora

Rocky Mountain Cancer Centers, Denver